Home  |  Contact

Cellosaurus 888-mel (CVCL_4632)

[Text version]

Cell line name 888-mel
Synonyms 888-MEL; 888 mel; 888mel; 888MEL; 888; Mel888; mel888; MG-888
Accession CVCL_4632
Resource Identification Initiative To cite this cell line use: 888-mel (RRID:CVCL_4632)
Comments From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
Omics: Array-based CGH.
Omics: Deep RNAseq analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732).
HLA typing Source: PubMed=9670966
Class I
HLA-AA*01,24
HLA-BB*52,55
HLA-CC*01:02,12:01
Disease Melanoma (NCIt: C3224)
Derived from metastatic site: Subcutaneous; soft palate.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_C612 (888A2 mel)
Originate from same individual CVCL_7943 ! 1290-mel
CVCL_DI11 ! 1858-mel a
CVCL_DI12 ! 1858-mel b
CVCL_DI13 ! 1858-mel c
CVCL_DI14 ! 1936-mel
CVCL_DI15 ! 1962-mel
CVCL_A1DN ! 888-EBV
Sex of cell Female
Category Cancer cell line
Web pages http://www.ott.nih.gov/erma/metastatic-melanoma-cancer-cell-line-888-mel
Publications

PubMed=8027550
Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R., Turetskaya R.L., Nedospasov S.A., Simonis T.B., Taubenberger J.K., Yannelli J.R., Mixon A., Restifo N.P., Herlyn M., Rosenberg S.A.
Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.
J. Immunol. 153:1225-1237(1994)

PubMed=8081556; DOI=10.1097/00002371-199407000-00002
Marincola F.M., Shamamian P., Simonis T.B., Abati A.D., Hackett J.A., O'Dea T., Fetsch P.A., Yannelli J.R., Restifo N.P., Mute J.J., Rosenberg S.A.
Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.
J. Immunother. Emphasis Tumor Immunol. 16:13-23(1994)

PubMed=8537970; DOI=10.1093/jnci/88.2.100
Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J.K., Yannelli J.R., Rosenberg S.A.
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
J. Natl. Cancer Inst. 88:100-108(1996)

PubMed=9670966
Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N., Panelli M., Parker K.K., Marincola F.M.
Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
J. Immunol. 161:877-889(1998)

PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A
Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A., Wunderlich J., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.
Int. J. Cancer 80:781-790(1999)

PubMed=10754339; DOI=10.4049/jimmunol.164.8.4382
Panelli M.C., Bettinotti M.P., Lally K., Ohnmacht G.A., Li Y., Robbins P., Riker A., Rosenberg S.A., Marincola F.M.
A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
J. Immunol. 164:4382-4392(2000)

PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004)

PubMed=16470173; DOI=10.1038/sj.jid.5700193
Wang E., Voiculescu S., Le Poole I.C., El-Gamil M., Li X., Sabatino M., Robbins P.F., Nickoloff B.J., Marincola F.M.
Clonal persistence and evolution during a decade of recurrent melanoma.
J. Invest. Dermatol. 126:1372-1377(2006)

PubMed=18172304; DOI=10.1158/0008-5472.CAN-07-1939
Sabatino M., Zhao Y., Voiculescu S., Monaco A., Robbins P., Karai L., Nickoloff B.J., Maio M., Selleri S., Marincola F.M., Wang E.
Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis.
Cancer Res. 68:122-131(2008)

PubMed=25502142; DOI=10.1038/ncomms6712
Muller J., Krijgsman O., Tsoi J., Robert L., Hugo W., Song C., Kong X., Possik P.A., Cornelissen-Steijger P.D.M., Geukes Foppen M.H., Kemper K., Goding C.R., McDermott U., Blank C., Haanen J., Graeber T.G., Ribas A., Lo R.S., Peeper D.S.
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Nat. Commun. 5:5712-5712(2014)

PubMed=25538140; DOI=10.15252/msb.20145450
Smit M.A., Maddalo G., Greig K., Raaijmakers L.M., Possik P.A., van Breukelen B., Cappadona S., Heck A.J.R., Altelaar A.F., Peeper D.S.
ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.
Mol. Syst. Biol. 10:772-772(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

Cross-references
Cell line databases/resources CGH-DB; 9308-4
Ontologies BTO; BTO:0002950
EFO; EFO_0006531
Chemistry resources PharmacoDB; 888mel_32_2019
Gene expression databases ArrayExpress; E-MTAB-2706
GEO; GSM206439
GEO; GSM218046
GEO; GSM274691
GEO; GSM1092556
GEO; GSM1507930
Other Wikidata; Q54605471
Polymorphism and mutation databases Cosmic; 876679
Cosmic; 877281
Cosmic; 905221
Cosmic; 1042621
Cosmic; 1238108
Cosmic; 1303045
Progenetix; CVCL_4632
Entry history
Entry creation04-Apr-2012
Last entry update20-May-2021
Version number22